Pharma Integrates 2020 Track 4


Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?

Welcome and opening remarks

TREVOR JONES CBE | Director | Arix Bioscience plc and e-Therapeutics plc
RICHARD TORBETT | Chief Executive Officer | ABPI

Partnership for innovation: how medicines will be made in future

We aspire to bring together the incredible talents of the pharma tech industry to bring forward the next generation of therapeutics – delivered in a cheaper and greener way.

It is now apparent that true collaboration holds the key to realising this aspiration. Science-led innovation on both sides of the fence is required to ensure access to the best experience, expertise and infrastructure wherever it resides. The ‘them and us’ outsourcing model of the past is being replaced, wherein innovation partnerships are being leveraged to produce much more efficient and effective drug discovery, development and supply.

Industry 4.0 and the digital transformation? New modalities? Big data? Shared risk and reward? Let’s properly re-imagine the future alliances essential to get new medicines to all those that need them across the globe.


RICHARD WEAVER | Founder and Managing Director and Senior Vice President – Pre-clinical Development | XenoGesis and Sygnature Discovery


DAVID HARRISON | Senior Director External Manufacturing & Alliances | UCB
ROSS BURN | Chief Executive Officer | CatSci and CDD
ROB HARRIS | Director | Beyond Quality
KATIE MURRAY | Technology Director Medicines Manufacturing Innovation Centre | CPI
DETLEF BEHRENS | Managing Director | Bay Pharma
ERIC DE VOS | VP of Global Innovation & Director of R&D Europe | Ajinomoto Bio-Pharma Services

The Power of Two – Making Strategic Partnerships Work

More than ever, our current situation has revealed the interdependency of pharma, CMOs and the supply chain. What’s the next evolution of strategic partnerships? How do organisational leaders create the right environment for true synergy and symbiosis? What role does technology play in forging stronger relationships and how can we creatively adapt current business models to work more collaboratively?


STUART NEEDLEMAN | Chief Commercial Officer | Piramal Pharma Solutions


NATALIA NOVAC | Senior Director, Emerging Technology & Innovation, Corporate Business Development | Eli Lilly
JULIETTE WHITE | Vice President, Global External Sourcing | AstraZeneca
NICK JOHNSON | Chief Strategy Officer | Cell and Gene Therapy Catapult
KAROLINA NIEWOLA | Business Development and Strategic Alliance Manager | iOnctura
NEIL JONES | Director Business Development, EU | Catalent Pharma Solutions

Take me to your leader

  • Experiences of how we can lead our teams through change when it is imposed upon us
  • How challenge creates opportunities
  • How we can harness new ways of working to a more productive future


KATHRYN SIMPSON | Business Consultant | Kathryn Simpson Consulting


PRIYA MANDE | Chief Operating Officer | PsiOxus Therapeutics
SIMON HIRST | Chief Executive Officer | Sygnature Discovery
EMMA SCEATS | Chief Executive | Isogenica
MICHELE LESUEUR | Hematology Oncology Business Unit Director | Celgene
KIMBERLY SMITH | Head of Global Research and Medical Strategy | ViiV Healthcare

Virtual Drinks Reception

 Sponsored By: Medicines Manufacturing Innovation Centre, CPI